Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Assessment of DNA Ploidy in the ProMisE molecular subgroups of endometrial cancer.

Gynecologic oncology - 1 Sept 2017

Proctor L, Pradhan M, Leung S, Cheng A, Lee C H, Soslow R A, Gilks C B, Talhouk A, McAlpine J M, Danielsen H E, Hoang L N

Abstract excerpt

OBJECTIVE: We sought to determine whether DNA ploidy correlates with the four molecular subgroups of endometrial carcinoma (EC) as determined using ProMisE (Proactive Molecular Risk Classifier for Endometrial Cancer). METHODS: 90 cases of EC previously characterized by clinicopathological parameters, outcomes, and ProMisE molecular subgroup (POLE EDM, MMR-D, p53 wt or p53 abn) were assessed for DNA ploidy using...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aneuploidy
Share to Diploidy
Share to DNA Mismatch Repair

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Polymerase II

Share to Ploidies

Share to Poly-ADP-Ribose Binding Proteins

Share to Receptors, Progesterone

Share to Tetraploidy

Source

Identifiers

PMID: 28647100
DOI: 10.1016/j.ygyno.2017.06.020

Genes

POLE

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Assessment of DNA Ploidy in the ProMisE molecular subgroups of endometrial cancer.PMID 28647100Read ↗

Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer.Semantic proximity Read ↗

Clinical features of ProMisE groups identify different phenotypes of patients with endometrial cancer.Semantic proximity Read ↗

The TCGA Molecular Classification of Endometrial Cancer and Its Possible Impact on Adjuvant Treatment DecisionsSemantic proximity Read ↗

Targeted Molecular Testing in Endometrial Carcinoma: Validation of a Clinically Driven Selective ProMisE Testing Protocol.Semantic proximity Read ↗

Harmonized molecular classification; assessment of a single-test ProMisE NGS tool.Semantic proximity Read ↗

Potential of molecular classification to guide fertility-sparing management among young patients with endometrial cancer.Semantic proximity Read ↗

Implementation of the ProMisE classifier and validation of its prognostic impact in Brazilian endometrial carcinomasSemantic proximity Read ↗

Prognostic significance of DNA ploidy in stage I endometrial cancer.Semantic proximity Read ↗

Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups.Semantic proximity Read ↗

Molecular subtype diagnosis of endometrial carcinoma: comparison of the next-generation sequencing panel and Proactive Molecular Risk Classifier for Endometrial Cancer classifier.Semantic proximity Read ↗

DNA ploidy in curettage specimens identifies high-risk patients and lymph node metastasis in endometrial cancerSemantic proximity Read ↗

Efficacy of fertility-sparing treatment with LNG-IUS is associated with different ProMisE subtypes of endometrial carcinoma or atypical endometrial hyperplasia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.